Table 1. Baseline demographics and clinical characteristics of patients in nICT and nICRT groups.
| Characteristics | nICT (n=38) | nICRT (n=17) | P value |
|---|---|---|---|
| Age (years), median [range] | 63.3 [50–74] | 62.8 [52–75] | 0.79 |
| Male, n (%) | 36 (94.7) | 13 (76.5) | 0.07 |
| Smoking history, n (%) | 28 (73.7) | 8 (47.1) | 0.07 |
| Drinking history, n (%) | 30 (78.9) | 9 (52.9) | 0.06 |
| Tumor location, n (%) | 0.61 | ||
| Proximal third | 2 (5.3) | 0 | |
| Middle third | 14 (36.8) | 6 (35.3) | |
| Distal third | 22 (57.9) | 11 (64.7) | |
| Clinical T stage, n (%) | 0.04 | ||
| cT2 | 0 | 2 (11.8) | |
| cT3 | 37 (97.4) | 13 (76.5) | |
| cT4a | 1 (2.6) | 2 (11.8) | |
| Clinical N stage, n (%) | 0.08 | ||
| N0 | 11 (28.9) | 2 (11.8) | |
| N1 | 20 (52.6) | 7 (41.2) | |
| N2 | 6 (15.8) | 8 (47.1) | |
| N3 | 1 (2.6) | 0 | |
| Clinical stage, n (%) | 0.52 | ||
| II | 11 (28.9) | 3 (17.6) | |
| III | 25 (65.8) | 12 (70.6) | |
| IVA | 2 (5.3) | 2 (11.8) | |
| Performance status (ECOG), n (%) | 0.47 | ||
| 0 | 29 (76.3) | 15 (88.2) | |
| 1 | 9 (23.7) | 2 (11.8) | |
nICT, neoadjuvant immunotherapy combined with chemotherapy; nICRT, neoadjuvant immunotherapy combined with chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group.